MPLT
NASDAQMapLight Therapeutics Inc.
MapLight Therapeutics Inc. (MPLT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for MPLT, including 6 insider trades, 3 SEC filings and 1 press release or news item. The most recent was published Nov 9, 2026.
MPLT rankings
Financial highlights
Full financials- Net income, TTM
- -$229.83M
- Free cash flow, TTM
- -$175.12M
- Cash
- $71.63M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks67-92%
2026-05-172026-11-08
Mix2590d
- Insider14(56%)
- SEC Filings7(28%)
- Other3(12%)
- Analyst1(4%)
Activity · 52 weeks14559 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRMapLight Therapeutics to Participate in Upcoming Investor ConferenceSAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conference: Event: 2026 Jefferies Global Healthcare Conference (London, UK)Date: Wednesday, November 18thFormat: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & Presentations" page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations. About MapLight Therapeutics MapLight Therapeutics is a clinical-stage biopharmaceutical
- INSIDERChief Discovery Officer Kreitzer Anatol sold $96,024 worth of Voting Common Stock (12,248 units at $7.84) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Scientific Officer Lillie James Woodruff sold $93,025 worth of Voting Common Stock (11,513 units at $8.08) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERGeneral Counsel Hanson Kristopher sold $72,882 worth of Voting Common Stock (9,020 units at $8.08) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Medical Officer Foff Erin Pennock sold $124,068 worth of Voting Common Stock (15,355 units at $8.08) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERCAO and Interim CFO Gillis Jonathan sold $82,149 worth of Voting Common Stock (10,167 units at $8.08) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Executive Officer Kroeger Christopher A. sold $595,423 worth of Voting Common Stock (73,691 units at $8.08) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- ANALYSTGuggenheim initiated coverage on MapLight TherapeuticsGuggenheim initiated coverage of MapLight Therapeutics with a rating of Neutral
- PRMapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of OptogeneticsAward honors foundational discoveries in optogenetics and circuit mapping These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight’s circuit-based approach to drug discovery SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics (NASDAQ:MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine. Dr. Deisseroth shares the honor with Peter Hegemann, Ph.D., of Humboldt University of Berlin, and Georg Nagel, Ph.D., of the University of Würzburg, for their discoveries concerning light-gated ion channels and optogeneti
- SECSEC Form EFFECT filed by MapLight Therapeutics Inc.EFFECT - MapLight Therapeutics, Inc. (0001770069) (Filer)
- SECSEC Form 424B3 filed by MapLight Therapeutics Inc.424B3 - MapLight Therapeutics, Inc. (0001770069) (Filer)
- INSIDERGeneral Counsel Hanson Kristopher sold $192,660 worth of Voting Common Stock (16,509 units at $11.67) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 137,044 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECAmendment: SEC Form S-1/A filed by MapLight Therapeutics Inc.S-1/A - MapLight Therapeutics, Inc. (0001770069) (Filer)
- SECSEC Form S-1 filed by MapLight Therapeutics Inc.S-1 - MapLight Therapeutics, Inc. (0001770069) (Filer)
- PRMapLight Therapeutics to Participate in Upcoming Investor ConferenceSAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conference: Event: Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY)Date: Monday, September 14th Format: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & Presentations" page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations. About MapLight Therapeutics MapLight Therapeutics is a clinical-stage bio
- INSIDERChief Discovery Officer Kreitzer Anatol was granted 6,020 units of Voting Common Stock, increasing direct ownership by 3% to 180,926 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERCAO and Interim CFO Gillis Jonathan was granted 8,242 units of Voting Common Stock, increasing direct ownership by 6% to 152,482 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Executive Officer Kroeger Christopher A. was granted 23,145 units of Voting Common Stock, increasing direct ownership by 2% to 1,269,600 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERGeneral Counsel Hanson Kristopher was granted 7,730 units of Voting Common Stock, increasing direct ownership by 5% to 153,553 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Medical Officer Foff Erin Pennock was granted 13,360 units of Voting Common Stock, increasing direct ownership by 4% to 312,261 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Scientific Officer Lillie James Woodruff was granted 7,730 units of Voting Common Stock, increasing direct ownership by 4% to 210,110 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERLarge owner Catalyst4, Inc. bought $50,072,000 worth of Voting Common Stock (4,400,000 units at $11.38) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
MPLT FAQ
9 questionsWhat is the latest news on MPLT?
In the last 30 days Quantisnow tracked 10 wire items for MPLT: 6 insider trades, 3 SEC filings and 1 press release or news item. The most recent was published on November 9, 2026.Is MPLT profitable?
No. MapLight Therapeutics Inc. reported a net loss of $229.83M for the twelve months ended Jun 30, 2026.How much cash and debt does MPLT have?
MapLight Therapeutics Inc. reported $71.63M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does MPLT stock trade?
MapLight Therapeutics Inc. (MPLT) is listed on NASDAQ.What sector and industry is MPLT in?
MapLight Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MapLight Therapeutics Inc. go public?
MapLight Therapeutics Inc. (MPLT) completed its IPO in 2025.What are analysts saying about MPLT?
Across the last 8 analyst actions on MapLight Therapeutics Inc., there were 0 upgrades and 2 downgrades. The most recent action was from Guggenheim: Neutral on 2026-10-06. Recent price targets range from $13.00 to $48.00.What companies are similar to MPLT?
Notable peers in the same industry include NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.). Compare MPLT side-by-side with any of them on Quantisnow.How can I track MPLT on Quantisnow?
Quantisnow aggregates MapLight Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MPLT to receive live email and push alerts on every new disclosure.